Literature DB >> 10510006

Treatment of refractory chylothorax with externalized pleuroperitoneal shunts in children.

A B Wolff1, M L Silen, E R Kokoska, B M Rodgers.   

Abstract

BACKGROUND: Traditional therapy for refractory chylothorax in the pediatric population has included pleurodesis and thoracic duct ligation. These procedures are associated with high morbidity and questionable success rates.
METHODS: We retrospectively reviewed our experience with 15 patients who underwent treatment for chylous effusions using pleuroperitoneal shunts with exteriorized pump chambers. Mean patient age at time of shunt placement was 2.1 (0.1 to 11.5) years and the most common indication (7 of 15) was refractory chylothorax following surgical correction of congenital heart disease. Mean chylothorax duration before shunt placement was 76 (5 to 810) days and shunts were in place for an average of 104 (12 to 365) days. A total of 19 chylous effusions (pleural or pericardial) were treated with shunts.
RESULTS: Nine of 11 right-sided chylothoraces, 5 of 6 left-sided chylothoraces, and 2 of 2 chylopericardia resolved with shunt therapy (84% total). Pleuroperitoneal shunting failed to clear the effusion in 3 children. There were six episodes of shunt malfunction that were repaired and two episodes of infection. Inguinal or umbilical hernia developed in 4 patients.
CONCLUSIONS: Externalized pleuroperitoneal shunting is a safe, effective, and minimally invasive treatment for children with refractory chylous effusions.

Entities:  

Mesh:

Year:  1999        PMID: 10510006     DOI: 10.1016/s0003-4975(99)00880-2

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  9 in total

1.  Idiopathic congenital chylothorax treated with octreotide.

Authors:  Paulo Rego Sousa; Henrique Leitão; Maria Carmo Camacho; José Luis Nunes
Journal:  BMJ Case Rep       Date:  2010-05-19

2.  Congenital chylothorax treated with octreotide.

Authors:  Yasin Sahin; Derya Aydin
Journal:  Indian J Pediatr       Date:  2005-10       Impact factor: 1.967

3.  Congenital Chylothorax of the Newborn: A Systematic Analysis of Published Cases between 1990 and 2018.

Authors:  Bernhard Resch; Gülsen Sever Yildiz; Friedrich Reiterer
Journal:  Respiration       Date:  2021-09-01       Impact factor: 3.580

4.  Somatostatin for postoperative chylothorax after surgery for children with congenital heart disease.

Authors:  Kyoung Ah Lim; Sung Hye Kim; June Huh; I-Seok Kang; Heung Jae Lee; Tae-Gook Jun; Pyo Won Park
Journal:  J Korean Med Sci       Date:  2005-12       Impact factor: 2.153

5.  The role of pleurodesis in the management of chylous pleural effusion after surgery for congenital heart disease.

Authors:  Poomiporn Katanyuwong; Joseph Dearani; David Driscoll
Journal:  Pediatr Cardiol       Date:  2009-08-25       Impact factor: 1.655

6.  Postoperative chylothorax development is associated with increased incidence and risk profile for central venous thromboses.

Authors:  M A McCulloch; M R Conaway; J A Haizlip; M L Buck; V E Bovbjerg; T R Hoke
Journal:  Pediatr Cardiol       Date:  2007-11-21       Impact factor: 1.655

7.  Incidence and etiology of chylothorax after congenital heart surgery in children.

Authors:  Parvin Akbari Asbagh; Mohammad Ali Navabi Shirazi; Aliakbar Soleimani; Maryam Razzaz; Naseradine Akbari Asbagh; Hussein Rayatzadeh; Mamak Shariat
Journal:  J Tehran Heart Cent       Date:  2014

8.  Use of Pleuroperitoneal Shunt in Chylothorax Related to Central Line Associated Thrombosis in Sickle Cell Disease.

Authors:  Elizabeth Spiwak; Chad Wiesenauer; Arun Panigrahi; Ashok Raj
Journal:  Children (Basel)       Date:  2018-01-02

9.  Lymphovenous anastomosis for the treatment of persistent congenital chylothorax in a low-birth-weight infant: A case report.

Authors:  Kenji Hayashida; Sho Yamakawa; Eri Shirakami
Journal:  Medicine (Baltimore)       Date:  2019-10       Impact factor: 1.817

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.